ST. PAUL, Minn., Dec. 20, 2018 /PRNewswire/ -- IGF Oncology, a clinical-stage company developing targeted therapies for cancer, today announced that its Founder and President, Hugh McTavish, Ph.D., will present at Biotech Showcase 2019, held January 6-9, 2019, at the Hilton San Francisco Union Square.
Dr. McTavish will present IGF Oncology's clinical pipeline, including its lead product, IGF-MTX, a conjugate of FDA-approved methotrexate with a proprietary derivative of insulin-like growth factor-1 (IGF) that is used to target the therapy to cancer cells that over-express the IGF receptor.
Details of IGF Oncology's presentation are as follows:
Event: | Biotech Showcase 2019 | |
Date: | Wednesday, January 9, 2019 | |
Time: | 10 a.m. (Pacific Time) | |
Location: | Hilton San Francisco Union Square |
About IGF Oncology
IGF Oncology is a clinical-stage company developing targeted therapies for cancer. The Company's lead product, IGF-MTX, is a conjugate of the drug methotrexate and a proprietary recombinant protein derivative of insulin-like growth factor-1 (IGF), the receptor for which is over-expressed by a number of cancers. A clinical study showed that IGF-MTX was effective at a concentration 12-fold lower than the lowest prescribed dose of methotrexate, across multiple tumor types, and without the dose-limiting side effect of cytopenia. The Company is currently conducting a Phase 1b/2a study with the Mayo Clinic in patients with myelodysplastic syndrome (MDS) and raising additional capital to fund this asset through potential approval.
Contacts:
Tiberend Strategic Advisors, Inc.
Brian Pinkston (Investors)
bpinkston@tiberend.com
(212) 375-6298
David Schemelia (Media)
dschemelia@tiberend.com
(212) 375-2686
SOURCE IGF Oncology
